RESULTS OF ANNUAL GENERAL MEETING

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'Aroa' or the 'Company') advises that in accordance with Listing Rule 3.13.2, details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX).
www.aroa.com

Contacts

investor@aroa.com

ASX ANNOUNCEMENT/MEDIA RELEASE
19 AUGUST 2026

Resolution Details			Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Res. Type	S or P	For	Against	Proxy's Discretion	Abstain/ Excluded	For	Against	Abstain*	Carried / Not Carried
1	RETIREMENT BY ROTATION AND RE-ELECTION OF DR CATHERINE MOHR	Ordinary	P	176,160,985 99.82%	140,045 0.08%	176,066 0.10%	29,535 -	177,062,542 99.92%	140,045 0.08%	29,535 -	Carried
2	ELECTION OF MR PAUL SHEARER	Ordinary	P	176,172,102 99.83%	123,427 0.07%	178,567 0.10%	32,535 -	177,008,160 99.93%	123,427 0.07%	32,535 -	Carried
3	AUDITOR'S REMUNERATION	Ordinary	P	176,147,799 99.54%	628,231 0.36%	178,566 0.10%	44,535 -	176,983,856 99.65%	628,231 0.35%	44,535 -	Carried
4	ISSUE OF DEFERRED STI FOR FY26 TO MR BRIAN WARD, CEO AND MANAGING DIRECTOR, UNDER THE AROA OMNIBUS PLAN	Ordinary	P	119,657,128 99.09%	920,823 0.76%	178,567 0.15%	56,382,722 -	120,493,186 99.24%	920,823 0.76%	56,382,722 -	Carried
5	ISSUE OF LTI FOR FY27 TO MR BRIAN WARD, CEO AND MANAGING DIRECTOR, UNDER THE AROA OMNIBUS PLAN	Ordinary	P	119,887,128 99.28%	690,823 0.57%	178,567 0.15%	56,382,722 -	120,723,186 99.43%	690,823 0.57%	56,382,722 -	Carried
6	INCREASE TOTAL AGGREGATE FEES FOR NON EXECUTIVE DIRECTORS	Ordinary	P	115,067,444 96.05%	4,556,672 3.80%	178,566 0.15%	56,844,058 -	115,903,501 96.22%	4,556,672 3.78%	56,844,058 -	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

AROA BIOSURGERY LIMITED
ARBN 638 867 473 NZCN 1980577
64 Richard Pearse Drive, Auckland 2022, New Zealand
AROA.COM